SGLT2 inhibitors and GLP-1 receptor agonists provide significant kidney and cardiovascular protection in chronic kidney disease patients beyond their blood sugar-lowering effects.
Beyond glucoseSGLT2i and GLP-1 RAs protect kidneys and hearts through mechanisms independent of blood sugar control
What the researchers found
SGLT2 inhibitors protect kidneys by restoring tubuloglomerular feedback and reducing renal injury, while GLP-1 RAs reduce oxidative stress and inflammation — both offering organ protection beyond glycemic control.
Why it matters
Demonstrates that these diabetes drugs should be considered essential kidney and heart medications, not just blood sugar treatments, for CKD patients.
The numbers in context
Reviews multiple landmark trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY, FLOW); summarizes mechanisms and outcomes.
How the study worked
Narrative review summarizing clinical trials and mechanistic studies evaluating SGLT2i and GLP-1 RA effects on kidney function, cardiovascular outcomes, and disease progression in CKD/DKD.
Who was studied
Patients with CKD and/or diabetic kidney disease
What this study cannot tell us
Narrative review format lacks the systematic rigor of meta-analysis; long-term outcomes data still accumulating for some populations; not all CKD stages equally studied.
How to read the evidence
Narrative review synthesizing clinical trial and mechanistic evidence; individual trials provide strong evidence but review format is less rigorous than systematic review.
When this study was published
Published in 2025, incorporating the latest clinical trial data on kidney and cardiovascular protection.
The bigger picture
The repurposing of diabetes medications as kidney and heart protectors represents one of the most important therapeutic advances in nephrology, potentially changing how CKD is managed regardless of diabetes status.
Questions still open
- Can combining SGLT2 inhibitors with GLP-1 RAs provide additive organ protection in CKD?
- At what CKD stage should these medications be initiated for maximum benefit?
Common questions
Can diabetes drugs protect kidneys even without diabetes?
How do GLP-1 medications protect the kidneys?
Read the original research
Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs.
Pharmaceuticals (Basel, Switzerland), 18(8)
Citation
Rabbani, Syed Arman; El-Tanani, Mohamed; Kumar, Rakesh; Saini, Manita; El-Tanani, Yahia; Sharma, Shrestha; Aljabali, Alaa A A; Hajeer, Eman; Rizzo, Manfredi. (2025). Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs.. Pharmaceuticals (Basel, Switzerland), 18(8). https://doi.org/10.3390/ph18081130